Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Common Equity (2016 - 2025)

Historic Common Equity for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to -$29.4 million.

  • Anaptysbio's Common Equity fell 13486.67% to -$29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 13486.67%. This contributed to the annual value of $70.9 million for FY2024, which is 1956.23% down from last year.
  • Per Anaptysbio's latest filing, its Common Equity stood at -$29.4 million for Q3 2025, which was down 13486.67% from -$44.7 million recorded in Q2 2025.
  • Anaptysbio's Common Equity's 5-year high stood at $385.7 million during Q2 2021, with a 5-year trough of -$44.7 million in Q2 2025.
  • Over the past 5 years, Anaptysbio's median Common Equity value was $148.4 million (recorded in 2023), while the average stood at $179.1 million.
  • Per our database at Business Quant, Anaptysbio's Common Equity surged by 648.59% in 2021 and then plummeted by 55280.9% in 2025.
  • Anaptysbio's Common Equity (Quarter) stood at $356.4 million in 2021, then dropped by 26.46% to $262.1 million in 2022, then plummeted by 66.39% to $88.1 million in 2023, then fell by 19.56% to $70.9 million in 2024, then plummeted by 141.51% to -$29.4 million in 2025.
  • Its Common Equity stands at -$29.4 million for Q3 2025, versus -$44.7 million for Q2 2025 and $34.0 million for Q1 2025.